MetaCap

Praxis Precision Medicines (PRAX) vs Summit Therapeutics (SMMT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Praxis Precision Medicines (PRAX) has outperformed Summit Therapeutics (SMMT) over the past year, gaining 76.9% versus a loss of 38.5%. Over five years, SMMT leads with a +92.8% price change compared with +19.5% for PRAX. Praxis Precision Medicines is the larger company by market cap ($8.40 billion vs $7.96 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PRAX+76.93%SMMT-38.54%
+136%+44%-47%
Nov 21, 20251 yearNov 20, 2026
PRAX+7.28%SMMT+85.98%
+526%+201%-125%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PRAX versus SMMT key metrics
MetricPRAXSMMT
Share price$300.43$9.95
Market cap$8.40B$7.96B
1-day change-3.37%-5.87%
YTD return+1.93%-43.11%
1-year return+76.93%-38.54%
5-year return+19.50%+92.83%
EPS (TTM)$-12.82$-1.06
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Revenue growth (YoY)-100.00%—
Net income (latest FY)$-303.27M$-1.08B
52-week high$392.70$29.23
52-week low$167.32$9.89
Distance from 52-week high-23.50%-65.96%
Analyst consensusstrong_buybuy
Avg. price target upside+124.49%+189.15%
Average volume479.87K6.68M
Shares outstanding27.95M799.76M
Employees168265
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PRAX has outperformed SMMT by 115.5 percentage points over the past year.

About Praxis Precision Medicines

PRAX stock →

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide.

Health Care · Biotechnology: Pharmaceutical Preparations · 168 employees

About Summit Therapeutics

SMMT stock →

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).

Health Care · Biotechnology: Pharmaceutical Preparations · 265 employees

PRAX vs SMMT FAQ

Which is bigger, Praxis Precision Medicines or Summit Therapeutics?

Praxis Precision Medicines (PRAX) is larger, with a market capitalization of $8.40B compared with $7.96B for Summit Therapeutics (SMMT).

Which stock has performed better over the past year, PRAX or SMMT?

PRAX returned +76.93% over the past 12 months, compared with -38.54% for SMMT (price return, excluding dividends). Past performance does not predict future results.

Are Praxis Precision Medicines and Summit Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons